Ocugen Résultats passés
Passé contrôle des critères 0/6
Ocugen's earnings have been declining at an average annual rate of -21.4%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 80.2% per year.
Informations clés
-21.4%
Taux de croissance des bénéfices
68.0%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 17.0% |
| Taux de croissance des recettes | 80.2% |
| Rendement des fonds propres | -294.7% |
| Marge nette | -618.2% |
| Prochaine mise à jour des résultats | 08 Nov 2024 |
Mises à jour récentes des performances passées
Recent updates
Ocugen announces peer-reviewed publication on COVID-19 vaccine
Sep 14Ocugen initiated with Buy at Mizuho citing favorable setup ahead of key readout
Aug 23Ocugen Q2 2022 Earnings Preview
Aug 04Ocugen: A First Take
Jul 18Ocugen in renewed focus as FDA wants COVID boosters to fight Omicron variant
Jul 05Ventilation des recettes et des dépenses
Comment Ocugen gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 7 | -45 | 28 | 0 |
| 31 Mar 24 | 7 | -58 | 30 | 0 |
| 31 Dec 23 | 6 | -63 | 32 | 0 |
| 30 Sep 23 | 3 | -82 | 34 | 0 |
| 30 Jun 23 | 3 | -90 | 34 | 0 |
| 31 Mar 23 | 3 | -86 | 34 | 0 |
| 31 Dec 22 | 2 | -87 | 35 | 0 |
| 30 Sep 22 | 0 | -74 | 36 | 0 |
| 30 Jun 22 | 0 | -63 | 32 | 0 |
| 31 Mar 22 | 0 | -69 | 29 | 0 |
| 31 Dec 21 | 0 | -58 | 23 | 0 |
| 30 Sep 21 | 0 | -48 | 18 | 0 |
| 30 Jun 21 | 0 | -47 | 15 | 0 |
| 31 Mar 21 | 0 | -38 | 10 | 0 |
| 31 Dec 20 | 0 | -34 | 8 | 0 |
| 30 Jun 20 | 0 | -30 | 8 | 1 |
| 31 Mar 20 | 0 | -18 | 7 | -3 |
| 31 Dec 19 | 0 | -20 | 6 | 0 |
| 30 Sep 19 | 0 | -39 | 6 | 9 |
| 30 Jun 19 | 0 | -18 | 6 | 4 |
| 31 Mar 19 | 0 | -19 | 6 | 11 |
| 31 Dec 18 | 0 | -18 | 6 | 10 |
Des revenus de qualité: OCGN is currently unprofitable.
Augmentation de la marge bénéficiaire: OCGN is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: OCGN is unprofitable, and losses have increased over the past 5 years at a rate of 21.4% per year.
Accélération de la croissance: Unable to compare OCGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: OCGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement des fonds propres
ROE élevé: OCGN has a negative Return on Equity (-294.74%), as it is currently unprofitable.